Int J Impot Res:霉酚酸酯对TGF-β诱导的佩罗尼氏病的抗纤维化作用研究

2019-05-02 AlexYang MedSci原创

最近,有研究人员评估了霉酚酸酯(MMF)对由转化生长因素β(TGF-β)注射诱导的佩罗尼氏病(PD)小鼠阴茎白膜的组织学、组化和体视学变化的影响。研究包括了20只雄性Wistar小鼠,并分成呢个4个组:对照组;TGF-β组(TGF-β注射);MMF-7d组(TGF-β注射7天后MMF处理组)和MMF-30d组(TGF-β注射30天后MMF处理组)。体视学评估包括白膜结缔组织不同类型连接纤维的相对大

最近,有研究人员评估了霉酚酸酯(MMF)对由转化生长因素β(TGF-β)注射诱导的佩罗尼氏病(PD)小鼠阴茎白膜的组织学、组化和体视学变化的影响。

研究包括了20只雄性Wistar小鼠,并分成4个组:对照组;TGF-β组(TGF-β注射);MMF-7d组(TGF-β注射7天后MMF处理组)和MMF-30d组(TGF-β注射30天后MMF处理组)。体视学评估包括白膜结缔组织不同类型连接纤维的相对大小。组化分析阐释了白膜中弹性蛋白的片段化和降解。该过程在MMFD-7d组中部分的恢复,且在MMF-30d组中基本接近正常。另外,在TGF-β(59.4±5.53)和MMF-7d(49±18.2)组中,胶原蛋白III/胶原蛋白I比例增加,而在MMF-30d组中,该比例减少(28.7±4)且接近正常。

最后,研究人员指出,TGF-β注射在患有PD的Wistar小鼠中能够促进阴茎白膜纤维化的改变。在该模型中,MMF是作为一种再生抗纤维化药物。

原始出处:

Thiago Antoniassi, Fernando Nestor Fácio Júnior, Luís Cesar Fava Spessoto et al. Anti-fibrotic effect of mycophenolate mofetil on Peyronie's disease experimentally induced with TGF-β. Int J Impot Res. 18 April 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035888, encodeId=cefb2035888ee, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Dec 06 18:29:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053957, encodeId=b8f9205395e98, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Fri Oct 04 05:29:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425933, encodeId=f4f51425933a1, content=<a href='/topic/show?id=646226e9571' target=_blank style='color:#2F92EE;'>#佩罗尼氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26795, encryptionId=646226e9571, topicName=佩罗尼氏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f324016624, createdName=马龙, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441375, encodeId=a0a314413e5ea, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503531, encodeId=f29b150353199, content=<a href='/topic/show?id=77079889e8e' target=_blank style='color:#2F92EE;'>#霉酚酸酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98897, encryptionId=77079889e8e, topicName=霉酚酸酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd989654253, createdName=yuanming10, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575111, encodeId=3f5115e511159, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=)]
    2019-12-06 changhe713
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035888, encodeId=cefb2035888ee, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Dec 06 18:29:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053957, encodeId=b8f9205395e98, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Fri Oct 04 05:29:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425933, encodeId=f4f51425933a1, content=<a href='/topic/show?id=646226e9571' target=_blank style='color:#2F92EE;'>#佩罗尼氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26795, encryptionId=646226e9571, topicName=佩罗尼氏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f324016624, createdName=马龙, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441375, encodeId=a0a314413e5ea, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503531, encodeId=f29b150353199, content=<a href='/topic/show?id=77079889e8e' target=_blank style='color:#2F92EE;'>#霉酚酸酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98897, encryptionId=77079889e8e, topicName=霉酚酸酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd989654253, createdName=yuanming10, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575111, encodeId=3f5115e511159, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035888, encodeId=cefb2035888ee, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Dec 06 18:29:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053957, encodeId=b8f9205395e98, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Fri Oct 04 05:29:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425933, encodeId=f4f51425933a1, content=<a href='/topic/show?id=646226e9571' target=_blank style='color:#2F92EE;'>#佩罗尼氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26795, encryptionId=646226e9571, topicName=佩罗尼氏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f324016624, createdName=马龙, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441375, encodeId=a0a314413e5ea, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503531, encodeId=f29b150353199, content=<a href='/topic/show?id=77079889e8e' target=_blank style='color:#2F92EE;'>#霉酚酸酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98897, encryptionId=77079889e8e, topicName=霉酚酸酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd989654253, createdName=yuanming10, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575111, encodeId=3f5115e511159, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035888, encodeId=cefb2035888ee, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Dec 06 18:29:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053957, encodeId=b8f9205395e98, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Fri Oct 04 05:29:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425933, encodeId=f4f51425933a1, content=<a href='/topic/show?id=646226e9571' target=_blank style='color:#2F92EE;'>#佩罗尼氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26795, encryptionId=646226e9571, topicName=佩罗尼氏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f324016624, createdName=马龙, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441375, encodeId=a0a314413e5ea, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503531, encodeId=f29b150353199, content=<a href='/topic/show?id=77079889e8e' target=_blank style='color:#2F92EE;'>#霉酚酸酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98897, encryptionId=77079889e8e, topicName=霉酚酸酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd989654253, createdName=yuanming10, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575111, encodeId=3f5115e511159, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2035888, encodeId=cefb2035888ee, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Dec 06 18:29:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053957, encodeId=b8f9205395e98, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Fri Oct 04 05:29:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425933, encodeId=f4f51425933a1, content=<a href='/topic/show?id=646226e9571' target=_blank style='color:#2F92EE;'>#佩罗尼氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26795, encryptionId=646226e9571, topicName=佩罗尼氏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f324016624, createdName=马龙, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441375, encodeId=a0a314413e5ea, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503531, encodeId=f29b150353199, content=<a href='/topic/show?id=77079889e8e' target=_blank style='color:#2F92EE;'>#霉酚酸酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98897, encryptionId=77079889e8e, topicName=霉酚酸酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd989654253, createdName=yuanming10, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575111, encodeId=3f5115e511159, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2035888, encodeId=cefb2035888ee, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Dec 06 18:29:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053957, encodeId=b8f9205395e98, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Fri Oct 04 05:29:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425933, encodeId=f4f51425933a1, content=<a href='/topic/show?id=646226e9571' target=_blank style='color:#2F92EE;'>#佩罗尼氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26795, encryptionId=646226e9571, topicName=佩罗尼氏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f324016624, createdName=马龙, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441375, encodeId=a0a314413e5ea, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503531, encodeId=f29b150353199, content=<a href='/topic/show?id=77079889e8e' target=_blank style='color:#2F92EE;'>#霉酚酸酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98897, encryptionId=77079889e8e, topicName=霉酚酸酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd989654253, createdName=yuanming10, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575111, encodeId=3f5115e511159, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat May 04 04:29:00 CST 2019, time=2019-05-04, status=1, ipAttribution=)]
    2019-05-04 风铃826